Latest stories on MYGN
Myriad Uranium Announces Further Phase II Drill Results from Copper Mountain
StockTitan54 · neutralproduct/pr
Myriad Genetics assumed with a Neutral at UBS
The Fly50 · neutralanalyst
Peer-reviewed 411-patient study reports low infection rates with Myriad™ in complex soft tissue reconstruction
PR Newswire63 · neutralproduct/pr
Myriad Genetics downgraded at Piper Sandler on structural challenges
Seeking Alpha34 · bearishanalyst
Myriad Genetics shares fall 7.1% after Piper Sandler downgrade
InvestorsHub34 · bearishanalyst
Why is Myriad Genetics stock tumbling today?
Investing.com Markets34 · bearishgeneral
Piper Sandler cuts Myriad Genetics stock rating on profit concerns
Investing.com Analyst Ratings34 · bearishanalyst
Myriad Genetics downgraded to Underweight from Overweight at Piper Sandler
The Fly34 · bearishanalyst
Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference
StockTitan55 · neutralgeneral
CORRECTION FROM SOURCE: Myriad Uranium Announces Preliminary Radiometric Results from Lucky Cliff Drilling
StockTitan53 · neutralproduct/pr
Myriad Uranium Completes Acquisition of Rush Rare Metals
Business Insider62 · neutralm&a
Myriad Uranium Completes Acquisition of Rush Rare Metals
StockTitan62 · neutralm&a
Myriad Uranium Announces Preliminary Radiometric Results from Lucky Cliff Drilling
StockTitan56 · neutralgeneral
MYGN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Myriad Genetics Inc.
Business Insider50 · neutralgeneral
Myriad Genetics price target lowered to $3 from $5 at Stephens
The Fly34 · bearishanalyst
Myriad Genetics (MYGN) Securities Investigation Notice - Levi & Korsinsky
PR Newswire28 · bearishgeneral
MYGN SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Myriad Genetics
PR Newswire34 · bearishgeneral
Why Did RBLX, HTZ, MYGN Stocks Plunge To 52-Week Lows Last Week?
Stocktwits News32 · bearishgeneral
Myriad Genetics: Strong Oncology Demand, But Monetization Breaks Down
Seeking Alpha48 · neutralgeneral
Myriad Genetics, Inc. 2026 Q2 - Results - Earnings Call Presentation
Seeking Alpha50 · neutralearnings
Myriad outlines $770M-$790M 2026 revenue and 66%-67% gross margin ranges while suspending adjusted EBITDA guidance
Seeking Alpha34 · bearishearnings
Myriad Genetics, Inc. (MYGN) Q2 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
Myriad Genetics GAAP EPS of -$0.46 misses by $0.19, revenue of $190.7M misses by $15.33M
Seeking Alpha34 · bearishearnings
MYRIAD GENETICS INC (MYGN) files 8-K
SEC 8-K50 · neutralgeneral